ArticleFrontiers in psychiatry2025
Introducing the addictive daydreaming scale: development and Polish validation of the ADS-20 and ADS-5.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Maladaptive daydreaming (MD) is a pattern of excessive, compulsive fantasizing associated with functional impairment. While its classification remains debated, increasing evidence suggests that it may be understood as an addictive form of emotion regulation. This study aimed to develop and validate a new self-report tool, grounded in the behavioral addiction framework, for screening and assessing the severity of MD, and to examine its potential clinical utility. Methods: A mixed-clinical (N = 182) and non-clinical (N = 231) sample completed the Addictive Daydreaming Scale (ADS) in two forms: a 20-item full version (ADS-20) and a 5-item screening test (ADS-5), together with established measures of MD, quality of life, and self-rated impact of daydreaming. Results: Psychometric analyses confirmed that both the ADS-20 and ADS-5 demonstrated high reliability and strong content, criterion, and construct validity. ADS scores were more strongly correlated with both the psychological and social domains of quality of life than Maladaptive Daydreaming Scale scores, supporting its sensitivity to functional impairment. Cut-off scores of ≥42 (ADS-20) and ≥8 (ADS-5) showed good accuracy for identifying clinically significant cases. Conclusions: The ADS-20 and ADS-5 are reliable, valid instruments for identifying and assessing addictive features of maladaptive daydreaming. Their use may support improved clinical detection, assessing the severity of MD and help conceptualize it within the behavioral addictions framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.